222 related articles for article (PubMed ID: 16227141)
1. Effects of carvedilol on oxidative stress and chronotropic response to exercise in patients with chronic heart failure.
Castro P; Vukasovic JL; Chiong M; Díaz-Araya G; Alcaino H; Copaja M; Valenzuela R; Greig D; Pérez O; Corbalan R; Lavandero S
Eur J Heart Fail; 2005 Oct; 7(6):1033-9. PubMed ID: 16227141
[TBL] [Abstract][Full Text] [Related]
2. Effects of carvedilol on ventriculo-arterial coupling in patients with heart failure.
Razzolini R; Tarantini G; Boffa GM; Orlando S; Iliceto S
Ital Heart J; 2004 Jul; 5(7):517-22. PubMed ID: 15487269
[TBL] [Abstract][Full Text] [Related]
3. [Effects of carvedilol on functional capacity, left ventricular function, catecholamines and oxidative stress in patients with chronic heart failure].
Castro P; Pérez O; Greig D; Díaz-Araya G; Moraga F; Chiong M; Troncoso R; Padilla I; Vukasovic JL; Corbalán R; Lavandero S
Rev Esp Cardiol; 2004 Nov; 57(11):1053-8. PubMed ID: 15544754
[TBL] [Abstract][Full Text] [Related]
4. Effects of carvedilol, a vasodilator-beta-blocker, in patients with congestive heart failure due to ischemic heart disease. Australia-New Zealand Heart Failure Research Collaborative Group.
Circulation; 1995 Jul; 92(2):212-8. PubMed ID: 7600653
[TBL] [Abstract][Full Text] [Related]
5. Effects of carvedilol on left ventricular function and oxidative stress in infants and children with idiopathic dilated cardiomyopathy: a 12-month, two-center, open-label study.
Bajcetic M; Kokic Nikolic A; Djukic M; Kosutic J; Mitrovic J; Mijalkovic D; Jovanovic I; Simeunovic S; Spasic MB; Samardzic R
Clin Ther; 2008 Apr; 30(4):702-14. PubMed ID: 18498919
[TBL] [Abstract][Full Text] [Related]
6. Impact of initiating carvedilol before angiotensin-converting enzyme inhibitor therapy on cardiac function in newly diagnosed heart failure.
Sliwa K; Norton GR; Kone N; Candy G; Kachope J; Woodiwiss AJ; Libhaber C; Sareli P; Essop R
J Am Coll Cardiol; 2004 Nov; 44(9):1825-30. PubMed ID: 15519014
[TBL] [Abstract][Full Text] [Related]
7. Concentration of BNP, endothelin 1, pro-inflammatory cytokines (TNF-alpha, IL-6) and exercise capacity in patients with heart failure treated with carvedilol.
Nessler J; Nessler B; Kitliński M; Gackowski A; Piwowarska W; Stepniewski M
Kardiol Pol; 2008 Feb; 66(2):144-51; discussion 152-3. PubMed ID: 18344152
[TBL] [Abstract][Full Text] [Related]
8. Nonselective beta-adrenergic blocking agent, carvedilol, improves arterial baroflex gain and heart rate variability in patients with stable chronic heart failure.
Mortara A; La Rovere MT; Pinna GD; Maestri R; Capomolla S; Cobelli F
J Am Coll Cardiol; 2000 Nov; 36(5):1612-8. PubMed ID: 11079666
[TBL] [Abstract][Full Text] [Related]
9. [A failed improvement in pulmonary function and exercise capacity with carvedilol in congestive heart failure despite an excellent effect on left ventricular function].
Guazzi M; Pontone G; Trevisi N; Lomanto M; Matturri M; Agostoni P
Cardiologia; 1998 Feb; 43(2):181-7. PubMed ID: 9557374
[TBL] [Abstract][Full Text] [Related]
10. Effect of Carvedilol on Serum Heart-type Fatty Acid-binding Protein, Brain Natriuretic Peptide, and Cardiac Function in Patients With Chronic Heart Failure.
Sun YP; Wei CP; Ma SC; Zhang YF; Qiao LY; Li DH; Shan RB
J Cardiovasc Pharmacol; 2015 May; 65(5):480-4. PubMed ID: 25945865
[TBL] [Abstract][Full Text] [Related]
11. Low-dose carvedilol improves left ventricular function and reduces cardiovascular hospitalization in Japanese patients with chronic heart failure: the Multicenter Carvedilol Heart Failure Dose Assessment (MUCHA) trial.
Hori M; Sasayama S; Kitabatake A; Toyo-oka T; Handa S; Yokoyama M; Matsuzaki M; Takeshita A; Origasa H; Matsui K; Hosoda S;
Am Heart J; 2004 Feb; 147(2):324-30. PubMed ID: 14760332
[TBL] [Abstract][Full Text] [Related]
12. Carvedilol improves left ventricular function and symptoms in chronic heart failure: a double-blind randomized study.
Olsen SL; Gilbert EM; Renlund DG; Taylor DO; Yanowitz FD; Bristow MR
J Am Coll Cardiol; 1995 May; 25(6):1225-31. PubMed ID: 7722114
[TBL] [Abstract][Full Text] [Related]
13. Sudden cardiac death risk factors in patients with heart failure treated with carvedilol.
Nessler J; Nessler B; Kitliński M; Libionka A; Kubinyi A; Konduracka E; Piwowarska W
Kardiol Pol; 2007 Dec; 65(12):1417-22; discussion 1423-4. PubMed ID: 18181053
[TBL] [Abstract][Full Text] [Related]
14. Randomised, placebo-controlled trial of carvedilol in patients with congestive heart failure due to ischaemic heart disease. Australia/New Zealand Heart Failure Research Collaborative Group.
Lancet; 1997 Feb; 349(9049):375-80. PubMed ID: 9033462
[TBL] [Abstract][Full Text] [Related]
15. Differences between beta-blockers in patients with chronic heart failure and chronic obstructive pulmonary disease: a randomized crossover trial.
Jabbour A; Macdonald PS; Keogh AM; Kotlyar E; Mellemkjaer S; Coleman CF; Elsik M; Krum H; Hayward CS
J Am Coll Cardiol; 2010 Apr; 55(17):1780-7. PubMed ID: 20413026
[TBL] [Abstract][Full Text] [Related]
16. Role of beta-adrenergic receptor gene polymorphisms in the long-term effects of beta-blockade with carvedilol in patients with chronic heart failure.
Metra M; Covolo L; Pezzali N; Zacà V; Bugatti S; Lombardi C; Bettari L; Romeo A; Gelatti U; Giubbini R; Donato F; Dei Cas L
Cardiovasc Drugs Ther; 2010 Feb; 24(1):49-60. PubMed ID: 20352314
[TBL] [Abstract][Full Text] [Related]
17. Limited predictive value of cardiopulmonary exercise indices in patients with moderate chronic heart failure treated with carvedilol.
Corrà U; Mezzani A; Bosimini E; Scapellato F; Temporelli PL; Eleuteri E; Giannuzzi P
Am Heart J; 2004 Mar; 147(3):553-60. PubMed ID: 14999209
[TBL] [Abstract][Full Text] [Related]
18. Influence of carvedilol on the benefits of physical training in patients with moderate chronic heart failure.
Forissier JF; Vernochet P; Bertrand P; Charbonnier B; Monpère C
Eur J Heart Fail; 2001 Jun; 3(3):335-42. PubMed ID: 11378005
[TBL] [Abstract][Full Text] [Related]
19. Effects of carvedilol on plasma B-type natriuretic peptide concentration and symptoms in patients with heart failure and preserved ejection fraction.
Takeda Y; Fukutomi T; Suzuki S; Yamamoto K; Ogata M; Kondo H; Sugiura M; Shigeyama J; Itoh M
Am J Cardiol; 2004 Aug; 94(4):448-53. PubMed ID: 15325927
[TBL] [Abstract][Full Text] [Related]
20. Betaxolol is equivalent to carvedilol in patients with heart failure NYHA II or III: result of a randomized multicenter trial (BETACAR Trial).
Figulla HR; Krzeminska-Pakula M; Wrabec K; Chochola J; Kalmbach C; Fridl P
Int J Cardiol; 2006 Nov; 113(2):153-60. PubMed ID: 16157399
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
